BioSpace News Archive

Fact.MR, A Market Research And Competitive Intelligence Provider – The global Psychotic Disorder Treatment market is bound to be valued US$ 13.6 Bn in 2022 and have a CAGR of 6.1% between 2022 and 2032.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rapid access to pathology test results is critical to high quality and efficient modern healthcare.

Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.

MorphoSys AG announces an update of its financial guidance for 2022, after preliminary completion of the latest evaluation of MorphoSys’ half year 2022 financial performance.

MorphoSys AG reported preliminary U.S. net product sales of Monjuvi® for the second quarter 2022 and announced an update of its financial guidance for 2022 based on the preliminary unaudited consolidated results for the first six months 2022 and following the license agreements with Human Immunology Biosciences, Inc. for felzartamab and MOR210.

Christopher Chen, CEO of ChenMed, a leading provider of primary care to underserved seniors, will be featured in a “Meet the Primary Care Market Movers” session at the 2022 National Primary Care Transformation Summit.

Centene Corporation announced its financial results for the second quarter ended June 30, 2022.

GenScript USA Inc., the world’s leading life-science research tools and services provider, announced its second annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research.

RepliCel Life Sciences Inc. announced it has now received and analyzed all data and images from independent laboratory testing of the DermaPreciseTM injector prototype and consumables evaluating the injection systems’ various depths and doses in donated human skin tissue.

RetinalGenix™ Technologies, Inc., announced the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies, Inc. Board of Directors.